Trial reportBMC anesthesiology2026
Perioperative nebulized budesonide and L-Cysteine reduce pulmonary complications after posterior skull base tumor resection: a randomized controlled trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPerioperative pulmonary complications are a leading cause of morbidity and mortality in patients undergoing Posterior skull base tumors surgery.
objectiveTo evaluate the efficacy and safety of perioperative nebulized inhalation of budesonide combined with L-cysteine in reducing pulmonary complications in patients undergoing surgery for posterior skull base tumors, explore subgroup-specific effects based on tumor location such as the jugular vein region, and identify independent risk factors for pulmonary complications.
methodsThis prospective, randomized, controlled trial was conducted at a tertiary academic medical center between May 1, 2020, and May 1, 2023. The trial was registered in the Chinese Clinical Trial Registry (ChiCTR2000032022) on 2020-04-17 prior to patient recruitment. Patients with posterior skull base tumors scheduled for surgical resection were randomly assigned to either the intervention group or the control group. Patients were stratified into four subgroups based on tumor location: cerebellopontine angle (CPA), clivus, foramen magnum, and jugular vein region. The primary outcome was the incidence of overall pulmonary complications within 30 days postoperatively, including pneumonia, acute respiratory distress syndrome (ARDS), atelectasis, and bronchospasm. Secondary outcomes included the severity of pulmonary complications using Clavien-Dindo classification, length of hospital stay (LOS), intensive care unit (ICU) admission rate, and mortality.
resultsA total of 1200 patients with posterior skull base tumors were included in the study. The intervention group had a significantly lower incidence of overall pulmonary complications than the control group (12.3% vs. 21.7%, P < 0.001). Subgroup analysis revealed consistent protective effects across all tumor locations, with the greatest magnitude observed in the foramen magnum subgroup (10.2% vs. 28.3%, P < 0.001) and jugular vein region subgroup (11.0% vs. 26.7%, P < 0.001), followed by the clivus (11.5% vs. 20.1%, P = 0.002) and CPA (13.1% vs. 19.8%, P = 0.012) subgroups.
conclusionPerioperative nebulized inhalation of budesonide combined with L-cysteine was independently associated with a reduced risk of pulmonary complications in patients with posterior skull base tumors, with consistent benefits across all tumor location subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.